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Background: L-asparaginases (E.C.3.5.1.1, L-ASNases) are successfully used as anti-neoplastic agents in the chemotherapy
of acute lymphoblastic leukemia (ALL) and therefore are of high interest for the medical and scientific community. In
the present study we report the recombinant, extracellular expression and affinity purification of L-asparaginase from
Erwinia chrysanthemi 3937 (ErL-ASNase) in E. coli.
Results: Recombinant E. coli strains were screened for their ability to express and translocate ErL-ASNase to the culture
medium. The strain E. coli Rosetta (DE3) exhibited the highest extracellular expression levels among all the strains tested
and it was chosen for further optimization and the development of purification protocol. Affinity adsorbents with
immobilized L-Asn, L-Asp and L-Glu were synthesized by solid-phase chemistry and evaluated for their ability to bind
and purify ErL-ASNase directly from the culture medium. The affinity adsorbent with immobilized L-Asp (L-Asp-Sepharose
CL-6B) showed the highest purifying ability for ErL-ASNase. Adsorption equilibrium studies revealed that the adsorption
of ErL-ASNase follows Langmuir isotherm with KD = 0.21 μM and maximum binding capacity 4.7 mg enzyme/g moist
wet adsorbent. This affinity adsorbent was used for the development of one-step purification protocol. The proposed
protocol is simple, fast, gentle and afforded ErL-ASNase with high purity and yield.
Conclusions: We show that the recombinant expression of ErL-ASNase in E. coli results in the secretion to the culture
medium due to the presence of its natural peptide leader at the N-terminus. We developed an L-Asp-based affinity
adsorbent which allowed the purification of the enzyme in one step, achieving high purity levels. This approach is
advantageous over the other conventional tag-based purification methods, which require additional treatment steps
for the cleavage and isolation of the affinity tags. Overall, the strategy employed for expression and purification of this
protein drug uses green chemistry principles allowing the reduction of processing time and purification steps, making
the approach more sustainable and attractive.
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L-asparaginase (E.C.3.5.1.1, L-ASNase) catalyzes the hy-
drolysis of L-asparagine to L-aspartic acid and ammonia.
The enzyme attracts attention due to its efficient use in
the therapy of Acute Lymphoblastic Leukemia (ALL) [1-3].
L-ASNase is also used in combination with other drugs for
the treatment of other type of malignancies such as non-
Hogkins Lymhoma, chronic lymphoblastic leukemia, lym-
phosarcoma, melanosarcoma [4,5]. In the case of ALL the
therapeutic function of L-ASNase is due to the fact that the
asparagine synthetase of the leukemic lymphoblasts is* Correspondence: Lambrou@aua.gr
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article, unless otherwise stated.downregulated resulting in deficiency of L-asparagine syn-
thesis [6-8]. Therefore, the survival of those cells is
dependent on the exogenous supply of L-asparagine from
the blood. L-ASNase depletes the available L-Asn in the
blood, causing inhibition of protein synthesis and apop-
tosis to the malignant cells [8,9]. It must be underlined
that the normal cells are not affected since they can
synthesize L-Asn.
L-ASNase is the only bacterial enzyme that has been
approved by the FDA for human therapy [10]. The two
approved preparations are from E. coli and E. chry-
santhemi [11]. The E. coli ASNase is the first choice
drug as it is capable of leading to remission very fast and
causing relatively mild toxic effects [12]. Nevertheless, in
cases where immunogenicity and allergic side effectsistry Central Ltd. This is an Open Access article distributed under the terms of
ttp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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switched to the Erwinia enzyme [13,14]. It has been re-
ported, that the two enzymes exhibit totally different im-
munogenicity patterns in patients [15].
Affinity chromatography is considered to be one of the
most refined and efficient techniques, which has been
widely used in downstream processing with outstanding
success in certain cases [16]. In this technique, the mol-
ecule of interest binds to another immobilized molecule,
most often called the ligand. Ideally, the ligand has such
structural and physicochemical properties that it is rec-
ognized specifically only by the target biomolecule [17].
As a result, the final purity depends on the specificity
between the ligand and the biomolecule as well as, the
strength of their interaction [18].
Periplasmic protein expression and potentially, extracel-
lular secretion in the growth medium facilitates enormously
the downstream processing protocol due to lower level of
extracellular expressed proteins compared to intracellular
ones [19-27]. As a result, higher protein purity can be
achieved applying less number of chromatographic steps.
The long-term usage of L-asparaginase leads to life-
threatening multiple toxic effects. Among its multiple
toxic effects, L-asparaginase induces allergic reactions
usually due to low purity enzyme preparations and the
presence of unwanted contaminations by bacterial proteins.
Therefore, efficient recombinant expression, coupled with
simple, rapid and low cost purification protocol would as-
sist the overall production scheme of such an important
enzyme, whose purity is extremely critical due to its use
for human treatment. The aim of the present work is to
study the optimization of the extracellular expression of
ErL-ASNase in E. coli by attaching its natural peptide
leader at the N-terminus. The secreted recombinant L-
ASNase was ultimately purified by applying an efficient
one-step affinity chromatographic protocol.
Experimental
Materials
L-Asn, L-Asp, L-Glu, trichloroacetic acid, 1,4-butanediol
diglycidyl ether and crystalline bovine serum albumin
(fraction V) were obtained from Sigma-Aldrich (U.S.A.).Table 1 E. coli strains used in the present study
E. coli strains Genotypes
XL1-Blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 p
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nup
galK16 rpsL(StrR) endA1 λ−
UT 5600 F− ara-14 leuB6 secA6 lacY1 proC14 tsx-67 Δ(ompT-fepC)2
BL21(DE3) F− ompT gal dcm lon hsdSB(rB
− mB
−) λ(DE3 [lacI lacUV5-T7
BL21(DE3)Star F− ompT gal dcm lon hsdSB(rB
− mB
−) λ(DE3),(cmR)
Rosetta(DE3) F− ompT hsdSB(rB
− mB
−) gal dcm (DE3) pRARE (CamR)
BL21(DE3)pLysS F− ompT gal dcm lon hsdSB(rB
− mB
−) λ(DE3) pLysS(cmR)Sepharose CL-6B were purchased from Pharmacia.
Nessler’s reagent was obtained from Fluka (Germany).
Isopropyl-beta-D-thiogalactoside (IPTG) was from Genaxis
(U.K.). Yeast extract, peptone, agar and glycerol were pur-
chased from Scharlau (Spain).
Solid phase synthesis of the affinity adsorbents
Synthesis of the affinity adsorbents was carried using a
two-step procedure as follows: i) Activation of agarose:
Sepharose CL-6B beads (5 g) were thoroughly washed
with double distilled water in a glass filter funnel and
drained. The washed beads were suspended in 1M
NaOH solution (5 mL) and shaken on a rotary shaker
(140 rpm, 25°C, 120 min). The beads were washed with
double distilled water to remove excess NaOH and 1,4-
butanediol diglycidyl ether (5 mL) was added to the
Sepharose CL-6B. The mixture was shaken at 140 rpm,
25°C for 12 h. After completion of the reaction the 1,4-
butanediol diglycidyl ether-activated Sepharose CL-6B
was washed with double distilled water.
ii) Coupling with the ligand (L-Asp, L-Glu, or L-Asn):
Activated Sepharose CL-6B (5 g) was resuspended in 20
mL KH2PO4, pH 7.5, along with either L-Asp or L-Glu
or L-Asn (1 g dissolved in 10 mL Na2CO3, pH 10). The
mixture was shaken on a rotary shaker (210 rpm, 25°C)
for 64 h. After completion of the reaction, the gel was
filtered, washed with distilled water and stored in water
at 4°C.
Optimization of extracellular expression of ErL-ASNase in
E. coli
ErL-ASNase cloned in pCR T7/CT TOPO vector as de-
scribed previously [28], was expressed in seven different
E. coli strains (Table 1) in order to investigate the ex-
pression levels as well as potential secretion in the culture
medium. A single colony of each E. coli strain harboring
the recombinant plasmid [28] was used to inoculate LB
medium containing 100 μg/mL ampicillin. Cultures were
grown overnight at 37°C under vigorous rotation (240
rpm). Subsequently, either LB or 2xYT or TB main cul-
tures supplemented with 100 μg/mL ampicillin, were in-
oculated with 1/100 of overnight cultures. Cell growthSupplier
roAB+ lacIq Δ(lacZ)M15] hsdR17(rK
− mK
+) Stratagene
G recA1 araD139 Δ(ara-leu)7697 galE15 Invitrogen
66 entA403 trpE38 rfbD1 rpsL109 xyl-5 mtl-1 thi-1 New England Biolabs




Figure 1 Evaluation of extracellular secretion of ErL-ASNase expressed by different E. coli strains (△: E. coli Rosetta(DE3); ◊: E. coli BL21
(DE3) Star; ☐: E. coli BL21(DE3); ○: E. coli TOP10). As time zero is considered the point at which IPTG is added. Cells were grown at 37°C as
described in text. The standard deviation for the specific activities (U/mg), evaluated from three independent determinations was found to be
less than 15%.
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ance at 600 nm reached 0.5-0.7, expression was induced
by the addition of IPTG to a final concentration of 1 mM.
Cultures were incubated at 37°C or 18°C and at different
time points cells were harvested by centrifugation at
10,000g (4°C) for 20 min, suspended in 50 mM KH2PO4
pH 7.5, sonicated (the cell suspensions were divided into
2-mL fractions, which were sonicated by applying short
pulses of 15 s; the process was repeated three times), and
centrifuged at 10,000g (4°C) for 20 min. The supernatant
was collected and L-ASNase activity was determined in
the intracellular extract as well as in the culture medium.1 2 3 4 5
37.2 kDaEnzymatic activity assay
Enzyme assays were performed at 37°C by measuring
the amount of ammonia liberated upon reaction with
Nessler’s reagent. Activities were measured as described
by Kotzia & Labrou [28]. One unit of L-ASNase activity
is defined as the amount of enzyme that liberates 1 μmol
of ammonia from L-Asn per min at 37°C. Protein con-
centrations were determined at 25°C by the method of
Bradford [29] using bovine serum albumin (fraction V)
as standard.Figure 2 Electrophoretic profiles of the culture media of the
E. coli strains that secreted the ErL-ASNase. Lane 1, protein
marker; Lane 2, culture medium from E. coli TOP10 strain; Lane 3,
culture medium from E. coli Rosetta(DE3); Lane 4, culture medium
from E. coli BL 21(DE3) Star; Lane 5, culture medium from E. coli BL
21(DE3) cells.Screening of affinity adsorbents for ErL-ASNase binding
Columns packed with affinity adsorbents (2 mL) were
washed with 50 mL double distilled H2O and equilibrated
with 30 mL of 20 mM KH2PO4, pH 7.5. Culture medium
supernatant containing the secreted ErL-ASNase (ap-
proximately 80 U) was dialysed overnight against 20 mM
KH2PO4 pH 7.5 and was loaded onto each column. Non-
adsorbent proteins were washed off with 30 mL of equili-
bration buffer. The adsorbent’s binding capacity wasdetermined as the proportion (%) of L-ASNase (units)
bound on the affinity adsorbent to the overall units
loaded.
Adsorption equilibrium studies
In a total volume of 1 mL of 20 mM KH2PO4, pH 7.5,
varying amounts of purified L-ASNase, previously dia-
lysed in 20 mM KH2PO4 pH 7.5, were mixed with 3 mg
of affinity adsorbent (L-Asp-Sepharose CL-6B). The sus-
pensions were shaken for 120 min in order for the sys-
tem to reach equilibrium. The suspension was then
Figure 3 Supernatant specific activities of ErL-ASNase expressed in culture medium by E. coli Rosetta(DE3) strain using different
culture media (△: TB; ☐: 2xYT; ○: LB) at 37°C. The standard deviation for the specific activities (U/mg), evaluated from three independent
determinations was found to be less than 15%.
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protein in the supernatant was determined by the
Bradford method [29]. Bound protein was calculated by
subtracting the amount of unbound protein from the
total amount of protein added. The data were analyzed
using Igor Pro software platform (Wavemetrics Co.).Purification of extracellular ErL-ASNase on immobilized
L-Asp affinity adsorbent
Culture medium (10 mL) was dialyzed overnight at 4°C
against binding buffer (20 mM KH2PO4, pH 7.5) contain-
ing different concentrations of NaCl (0.05-0.2 M) and
adjusted to different pH values (7.5-8.6) and loaded onto
L-Asp adsorbent, previously equilibrated with 30 mL of
the binding buffer. The column was kept closed for 10 minFigure 4 Supernatant specific activities of ErL-ASNase expressed in cu
culture media (◊: TB; ☐: 2xYT; △: LB) at 18°C. The standard deviation fo
determinations was found to be less than 15%.for the system to reach equilibrium. Subsequently, the col-
umn was exhaustively washed either with binding buffer
containing 2 M NaCl or with ice-cold ddH2O. Finally,
bound ErL-ASNase was eluted with 10 mL of 20 mM L-
Asp dissolved in 20 mM potassium phosphate buffer, pH
7.5. Both flow-through and washing fractions were kept
and the protein content was determined by Bradford and
analyzed by SDS-PAGE and activity assays.Electrophoresis
SDS polyacrylamide gel electrophoresis was performed
according to the method of Laemmli [30] on a slab gel
containing 12.5% (w/v) polyacrylamide (running gel) and
2.5% (w/v) stacking gel. The protein bands were stained
with Coomassie Brilliant Blue R-250.lture medium by E. coli Rosetta(DE3) strain using different
r the specific activities (U/mg), evaluated from three independent
Figure 5 Solid phase synthesis of the affinity adsorbent with immobilized L-Asp as an example.
Table 2 Binding (%) of ErL-ASNase to the affinity adsorbents
Adsorbent Binding (%)
L-Asn-Sepharose CL 6B 49
L-Asp-Sepharose CL 6B 71
L-Glu-Sepharose CL 6B 59
Binding (%) was expressed as the proportion (%) of ErL-ASNase (U) bound on
the affinity adsorbent to the overall units loaded. The standard deviation for
the enzyme activities (U), evaluated from three independent determinations
was found to be less than 10%.
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Optimization of extracellular expression of ErL-ASNase
in E. coli
In order to investigate and determine the optimum condi-
tions for extracellular expression of L-ASNase, seven E.
coli strains (Table 1) were evaluated for their ability to se-
crete the recombinant enzyme into the culture medium,
following induction by IPTG [31]. The results (Figure 1)
showed that four [E. coli TOP10, E. coli BL21(DE3), E. coli
BL21(DE3) Star, E. coli Rosetta(DE3)] out of seven strains
were able to secrete recombinant ErL-ASNase into the
culture medium at high level even during the early period
of induction i.e. the first hour. Figure 2 shows the electro-
phoretic profile of the proteins secreted in the culture
medium. It is evident that, the predominant protein band
corresponds to ErL-ASNase (~37.2 kDa). Among all
tested strains, E. coli Rosetta(DE3) secreted the highest
amounts of ErL-ASNase, whereas E. coli TOP10 secreted
the lowest. The other E. coli strains (XL-1 Blue, WT 5600,
BL21(DE3)pLysS) failed to secrete ErL-ASNase and there-
fore, E. coli Rosetta(DE3) was chosen for further study.
Three different culture medium compositions (LB, 2XYT
and TB) and two different temperatures (18°C and 37°C)
were evaluated for their effect on the enzyme production
and secretion, using the E. coli Rosetta(DE3) strain. As
shown in Figure 3 the TB medium appears to provide the
optimum conditions regarding the secretion of the en-
zyme, at 37°C. Surprisingly enough, unlike 37°C, TB was
the worst at 18°C (Figure 4). Under these conditions ap-
proximately 17,800 UI/L of enzyme were secreted in the
culture medium. On the other hand the intracellular ex-
pression level of ErL-ASNase was ~ 4,200 UI/L.
Synthesis and screening of affinity adsorbents for
ErL-ASNase binding
The synthesis of affinity adsorbents with immobilized L-
Asp, L-Asn and L-Glu was carried out on the solid phase(Sepharose CL-6B) (Figure 5) according to the well estab-
lished protocols [32]. Briefly, Sepharose CL-6B was acti-
vated by a bis-oxirane (1,4-butanediol diglycidyl ether)
under alkaline conditions and the activated Sepharose CL-
6B was substituted by L-Asp, L-Asn and L-Glu at pH 10.
In order to determine the most effective adsorbent, all ad-
sorbents were evaluated for their ability to bind and purify
ErL-ASNase from the extracellural medium. Dialyzed
supernatant (80 U, in 20 mM KH2PO4, pH 7.5), was
loaded on each adsorbent (2 mL). The columns were
washed with equilibration buffer and bound ErL-ASNase
was eluted with L-Asp (20 mM) dissolved in 20 mM
KH2PO4, pH 7.5. It has been shown [33] that L-Asp is a
strong competitive inhibitor (Ki ~ 80 μM) of L-ASNase.
All affinity adsorbents were able to bind ErL-ASNase at
pH 7.5 (Table 2). In particular, the adsorbent with immo-
bilized L-Asp exhibited the highest binding capacity,
followed closely by L-Glu, while L-Asn showed the lowest
capacity. Taking into consideration the above observation,
the adsorbent L-Asp-Sepharose CL-6B was selected for
further study.
Adsorption equilibrium studies
In the present work, equilibrium adsorption studies were
employed to characterize the interaction of ErL-ASNase
with the L-Asp-Sepharose CL-6B affinity adsorbent. This
approach gives a relationship between the concentration
Figure 6 Equilibrium adsorption of ErL-ASNase on L-Asp-Sepharose CL-6B affinity adsorbent in batch system. The plot describes the
equilibrium concentration of the enzyme in liquid-phase vs the equilibrium concentration in the solid-phase for the Langmuir isotherm.
Non-linear regression curve fitting was performed using the Igor Pro software (Wavemetrics Co.).
1 2 3 4 5 6 7 8
Figure 7 Electrophoretic profile of the purification protocol.
Lane 1, protein marker; Lane 2, extracellular medium. Lane 3, flow
through fraction; Lane 4, washing fraction, performed with ddH2O;
Lane 5, elution of ErL-ASNase after washing with ddH2O; Lane 6,
flow through fraction; Lane 7, washing fraction, performed with 2 M
NaCl; Lane 8, elution of ErL-ASNase after washing with 2 M NaCl.
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adsorbed to the adsorbent at equilibrium [17,32,34]. The
theoretical model most often used to characterize affin-
ity systems is the second-order reversible interaction,
where the enzyme is bound to the ligand by a monova-






where E is the enzyme in solution, L is the ligand, and E.L
is the enzyme-ligand complex. The parameters k1 and k2
are the forward and reverse rate constant, respectively.
From equation 1 the Langmuir isotherm, described by
equation 2, can be obtained [17,34]:
q ¼ qmaxc  = KD þ cð Þ ð2Þ
where q* is the adsorbate concentration at equilibrium
(mg/g adsorbent), c* is the equilibrium liquid phase con-
centration (mg/mL), qmax is the Langmuir isotherm
maximum capacity (mg/g adsorbent), and KD is the ap-
parent dissociation constant.
The batch adsorption of ErL-ASNase on L-Asp-
Sepharose CL-6B affinity adsorbent is shown in Figure 6.
The line corresponds to Langmuir isotherm which gives
the best fit for the experimental data. The calculated dis-
sociation constant was estimated to be KD = 0.21 μM.
This value falls within the range expected for a highly
selective affinity adsorbent [35-37]. The maximum
binding capacity qmax was estimated 4.7 mg/g moist wet
adsorbent.Purification of ErL-ASNase on immobilized L-Asp affinity
adsorbent
The challenge for the development of a purification
protocol is to be considerably fast, gentle, low cost and
efficient regarding yield and purity levels. Initial screen-
ing unveiled that the adsorbent L-Asp-Sepharose CL-6B
displayed the higher capacity and purification ability for
ErL-ASNase and consequently it was employed for the
development of a purification protocol. It is noteworthy
that bound ErL-ASNase on L-Asp adsorbent tolerated
washing steps with even 2 M NaCl with negligible loss
of protein. This is indicative of the strong binding of the
enzyme on the affinity adsorbent. However, despite the
fact that bound ErL-ASNase could resist against salt
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sulted in only moderate removal of non-specific bound
contaminating proteins (Figure 7, Lanes 4,7). Other
agents such as glycerol or sucrose that destabilizes
hydrogen bond interactions between molecules, failed to
remove non-specific bound contaminating proteins (data
not shown). Surprisingly enough we found that non-
specific contaminating proteins can be totally removed
after exhaustive washing with ddH20. This finding
agreed with the observation that salt concentration (0.1
M NaCl) present in the binding buffer, maximized the
binding specificity of the enzyme on the adsorbent at pH
7.5 (data not shown). The total absence of salt (as NaCl)
or salts at higher concentration (0.2 M NaCl) in this step
resulted in a decrease in binding specificity. These find-
ings led us to the development of single-step affinity
purification procedure for ErL-ASNase. Dialyzed culture
medium (20 mM KH2PO4, containing 0.1 M NaCl, pH
7.5), was applied directly on L-Asp-Sepharose CL6B ad-
sorbent, previously equilibrated with the dialysis buffer.
Washing step included exhaustive washing with ice-cold
ddH2O. Elution of ErL-ASNase was affected specifically
by 20 mM L-Asp with a recovery >80%. The purity of
the enzyme preparation was evaluated by SDS-PAGE
(Figure 7, Lane 5) and shown to be homogeneous.
The present method provides a simple and effective
way for preparing in one-step highly purified recom-
binant ErL-ASNase.
Concluding remarks
Given the existing high interest in L-ASNase serving as
a neoplastic agent and being a milestone for the treat-
ment of ALL, we focused on the development of an effi-
cient protocol for the expression and purification of this
protein drug. The achievement of high purity levels in
the case of pharmaceutical proteins is of great import-
ance and plays a vital role in therapeutic applications
[38,39]. Therefore, it is a challenging task to establish an
efficient protocol not only for the recombinant expres-
sion of a therapeutic protein, but also for its purification,
which must be simple, fast, mild and of low cost. Recently,
L-ASNase from E. coli was extracellular expressed by fus-
ing the gene coding for 6-His-tagged L-ASNase to the
pelB leader sequence. In that work the recombinant
6-His-tagged protein was purified from the culture
supernatant in a single step using Ni-NTA affinity chro-
matography [40,41]. However, this approach necessitates
additional purification steps such as the cleavage and the
removal of the 6-His-tag, which add to the overall cost of
the purification process.
In the present work we showed that recombinant ErL-
ASNase is efficiently expressed in E. coli Rosetta(DE3)
and secreted into the culture medium. The expression
levels were optimized by testing different E. coli strains,culture media, as well as temperature and incubation
times. The secreted recombinant protein was purified
directly from the culture medium, thereby simplifying
considerably the downstream processing. The purifica-
tion protocol was based on affinity adsorbent with
immobilized L-Asp as a ligand, which exhibited high
specificity and affinity for ErL-ASNase. The final purity
of the enzyme (as judged by SDS-PAGE) justifies the po-
tential for scaling up the whole process, taking also into
account the low-cost materials used.
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